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Abstract: Measurement of intestinal permeability (IP) is often used in the examination of inflammatory
gastrointestinal disorders. IP can be assessed by measurement of urinary recovery of ingested
non-metabolizable lactulose (L) and mannitol (M). The present study aimed to examine how
measurements of IP can be integrated in a NMR-based metabolomics approach for a simultaneous
quantification of L/M ratio and biomarker exploration. For this purpose, plasma and urine samples
were collected from five-day-old preterm piglets (n = 20) with gastrointestinal disorders (subjected to
intra-amniotic lipopolysaccharide (LPS, 1 mg/fetus)) after they had been administrated a 5% lactulose
and 5% mannitol solution (15 mL/kg). The collected plasma and urine samples were analyzed
by 1H NMR-based metabolomics. Urine L/M ratio measured by 1H NMR spectroscopy showed
high correlation with the standard measurement of the urinary recoveries by enzymatic assays
(r = 0.93, p < 0.05). Partial least squares (PLS) regressions and correlation analyses between L/M
ratio and NMR metabolomics data revealed that L/M ratio was positively correlated with plasma
lactate, acetate and succinate levels and negatively correlated with urinary hippuric acid and glycine.
In conclusion, the present study demonstrated that NMR metabolomics enables simultaneous IP
testing and discovery of biomarkers associated with an impaired intestinal permeability.
Keywords: intestinal barrier dysfunction; leaky gut; preterm infants; lipopolysaccharide (LPS);
prenatal inflammation; NMR metabolomics; lactulose
1. Introduction
The gut is one of the most crucial organs acting as a functional barrier for interaction with
the environment, and therefore, intestinal permeability (IP) plays an important role in health and
disease [1]. The intestinal barrier allows the absorption of nutrients while preventing the penetration of
macromolecules and microorganisms into the body [2]. Alterations in IP can be sign of an inflammatory
response to pathogens [3,4].
Immaturity of the immune system and digestive tract in preterm birth may lead to the
development of inflammatory diseases [2,5]. Altered IP and leaky gut have been reported during
gastrointestinal complications such as necrotizing enterocolitis (NEC) [6,7] and gut-associated sepsis,
suggesting failure of the immature intestine to properly develop the barrier function and adaption
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to extrauterine life [8,9]. NEC is the most common gastrointestinal disorder in premature infants,
causing significant neurodevelopmental mortality in preterm infants [10,11]. Gut diseases are often
described by a dysregulation of the colonic microbiota alongside their metabolic activities. The gut
microbiome is important in the attainment of energy and nutrients in preterm neonates, which is
essential for the fast development of organs together with the gut. A dysfunctional gut microbiome
in preterm neonates with NEC can restrain the accessibility of symbiotic metabolites, and different
neurotransmitters, which affects the development of the digestive, immune, and nervous systems in
infected neonates. The immature intestinal barrier in the preterm neonate has been shown to mature
postnatally. Thus, neonates with abnormal or delayed bacterial colonization of the gut may be at
an increased risk of intestinal inflammation and injury due to an immature or defective intestinal
barrier that allows the systemic entry of microbes, their products, or toxins from the gut lumen.
Metabolites can be considered as the signatures of biochemical activities and may be directly
associated with the disease phenotypes in biological systems. Urinary metabolite levels are affected
by energy and nutrient intake, metabolisms in the body and also environmental factors including
microbiota that keep a close cross-talk with the intestinal system. Thus, disorders in the gastrointestinal
tract might alter the metabolic levels of the body fluids which can be reflected in the blood and urine.
Determination of the IP metabolite biomarkers in plasma and urine by NMR-based metabolomics
could potentially be of importance in gastrointestinal disorders, particularly in preterm infants due
to the fact that metabolites can reflect the excessive fermentation of undigested nutrients in the
colon. In order to determine IP, conventionally a combination of non-metabolizable sugars such as
lactulose (L) and mannitol (M) is implemented by oral ingestion. The ratio of the urinary excretion of
lactulose, a relatively large molecule regarded as a measure of paracellular permeability, to mannitol,
a small molecule regarded as a measure of transcellular permeability, is used as an indicator of
the barrier function [12]. Under intestinal damage, the IP of the large molecules is increased while
the permeability of the small molecules is unchanged [13]. However, in the case of severe damage,
the permeability of the small molecules is decreased [14]. Therefore, L/M ratios can be considered as
an indicator of IP. Calculation of the ratio of sugars has the benefit of controlling the fluctuation in
urine dilution, gastric emptying, intestinal fluid volume, gastric transit time as well as impaired renal
excretion, providing a direct measurement of the paracellular absorptive capacity in the gastrointestinal
tract [15]. Traditionally lactulose and mannitol are determined by chromatographic methods or
enzymatic assays [16–18]. However, 1H NMR spectroscopy is a rapid and non-invasive method for
simultaneous detection and quantification of a large number of metabolites in complex biological
fluids in a single experiment. Consequently, 1H NMR spectroscopy could be an appropriate approach
for the simultaneous quantification of carbohydrates and exploration of metabolite biomarkers in
urine [19,20]. However, with NMR spectroscopy, the number of identifiable metabolites is lower than
LC-MS-based methods and is more expensive than the enzymatic assays methods.
In this study, determination of IP by using 1H NMR spectroscopy was first evaluated and
compared with a standard measurement of urinary lactulose and mannitol by enzymatic assays. Using
a piglet model for preterm infants, we hypothesized that an increased IP may be associated with
perturbations in urine and blood metabolites, and metabolite biomarkers reflecting changes in IP may
be revealed. To test this hypothesis, NMR metabolomics was used to evaluate the association between
impaired intestinal barrier function and the metabolome of premature piglet neonates predisposed to
a gastrointestinal disorder by investigating the correlations between IP measurements and the levels of
plasma and urine metabolites.
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2. Results
2.1. Method Elucidation
Plasma and urine samples from preterm newborn pigs were analyzed by 1H NMR spectroscopy,
and a total of 38 and 34 metabolites were assigned in plasma and urine biofluids, respectively
(Figure 1a,b).Metabolites 2019, 9, x 3 of 11 
 
 
Figure 1. 1H NMR spectra (obtained at 600 MHz) and assigned metabolites of (a) plasma and (b) urine. 
key: 1: acetate; 2: acetylcholine; 3: alanine; 4: 2-aminoadipate; 5: betaine; 6: choline; 7: citrate; 8: 
creatine; 9: creatinine; 10: dimethylamine; 11: ethanol; 12: glucose; 13: glutamate; 14: glutamine; 15: 
glycine; 16: isobutyrate; 17: isoleucine; 18: isopropanol; 19: lactate; 20: lactulose; 21: leucine; 22: lysine; 
23: mannitol; 24: methanol; 25: methionine; 26: myo-inositol; 27: N-acetylglutamate; 28: N-
acetylneuraminic acid; 29: propylene glycol; 30: pyruvate; 31: raffinose; 32: succinate; 33: taurine; 34: 
valine. 
For quantification of lactulose and mannitol, NMR resonances that do not overlap with other 
signals should preferably be chosen. Hence, mannitol’s doublet at 3.8 ppm and lactulose’s doublet at 
4.56 ppm were used for quantitative estimation of L/M ratio. The correlation between L/M ratio 
quantified by NMR spectroscopy and the standard measurement of L/M ratio was examined by linear 
regression. A strong correlation between L/M ratios determined with the standard assay and ratio 
obtained from quantification by NMR spectroscopy was obtained (r = 0.93, p < 0.05) (Figure 2). 
Figure 1. 1H NMR spectra (obtained at 600 MHz) and assigned metabolites of (a) plasma and
(b) urine. key: 1: acetate; 2: acetylcholine; 3: alanine; 4: 2-aminoadipate; 5: betaine; 6: choline; 7: citrate;
8: creatine; 9: creatinine; 10: dimethylamine; 11: ethanol; 12: glucose; 13: glutamate; 14: glutamine;
15: glycine; 16: isobutyrate; 17: isoleucine; 18: isopropanol; 19: lactate; 20: lactulose; 21: leucine;
22: lysine; 23: mannitol; 24: methanol; 25: methionine; 26: myo-inositol; 27: N-acetylglutamate;
28: N-acetylneuraminic acid; 29: propylene glycol; 30: pyruvate; 31: raffinose; 32: succinate; 33: taurine;
34: valine.
For quantification of lactulose and mannitol, NMR resonances that do not overlap with other
signals should preferably be chosen. Hence, mannitol’s doublet at 3.8 ppm and lactulose’s doublet
at 4.56 ppm were used for quantitative estimation of L/M ratio. The correlation between L/M ratio
quantified by NMR spectroscopy and the standard measurement of L/M ratio was examined by linear
regression. A strong correlation between L/M ratios determined with the standard assay and ratio
obtained from quantification by NMR spectroscopy was obtained (r = 0.93, p < 0.05) (Figure 2).
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Figure 2. Results of a linear regression between the measurement of lactulose/mannitol (L/M) ratio by
a standard assay and L/M ratio quantified by 1H NMR spectroscopy.
2.2. Biomarker Exploration
In order to elucidate correlations between the L/M ratio and the metabolomes derived from NMR,
partial least squares (PLS) models were performed between metabolites quantified from the obtained
NMR spectra and corresponding L/M ratios. A PLS model with one component (R2 = 0.75, Q2 = 0.50,
and root mean square error of cross validation (RMSECV) = 6.2 × 10−3) revealed that several plasma
metabolites had a significant correlation with the quantified urine L/M ratio (Figures 3a and S1a,b).
The most prominent metabolites in the PLS regression model are illustrated by the variable importance
in projection (VIP) score plot. The metabolites acet e, 2-hydroxybutyrate, 2-oxoglutarate, citrate,
glucose, lactate, succinate, and glutamate all had a VIP score above 1 and can, thus, be considered
important for the ability of the PLS regression model to build a quantitative relationship between
the quantified metabolites and the L/M ratio (Figures 3b and S1c,d). For the urine samples, a PLS
regression model with two components yielded an R2 value of 0.73, Q2 value of 0.51, and RMSECV of
6.2 × 10−3, showing a significant correlation between the urine metabolites and L/M ratio. (Figure 3c).
From the VIP score lot, it was evident that he urine metabolites hippuric acid, fumarate, succinate,
urea, glycine, choline, and alanine were the most important variables (Figure 3d).
PLS models were supplemented with correlations analyses between plasma and urine metabolites
and L/M ratio, which revealed significant positive correlations between the L/M ratio and plasma
2-hydroxybutyrate, 2-oxoglutarate, acetate, citrate, glucose, glutamate, lactate, and succinate (Figure 4).
Urinary hippuric acid showed a significant negative correlation with L/M ratio. Without reaching the
s gnificance level, the urine etabolites fumarate, choline, and succinate showed positive correlation
while glycine, alanine, and urea exhibited a negative correlation.
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Figure 4. Heat map of correlation analysis between the quantified plasma and urine metabolites and
quantified urine L/M ratio by 1H NMR spectroscopy. Stars indicate significant correlations (p < 0.05).
The heat map is colored based on Pearson’s correlation coefficient (r). The red and blue color of every
cell illustrates the Pearson’s correlation coefficient value, while deeper colors indicate higher positive
(red) or negative (blue) correlation coefficients.
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3. Discussion
3.1. Method Elucidation
Evaluation of IP is useful for the diagnosis of small intestinal diseases and evaluation of treatment
intervention studies [21] especially in the early life of immature infants [5]. Minimally-absorbed
and non-metabolized sugars such as lactulose and mannitol are commonly used for the assessment
of barrier functions. The estimation of L/M ratios by HPLC has some analytical difficulties such
as the necessity for being coupled to a pulsed amperometric, refractive index, evaporative light
scattering detector, fluorescence, or mass spectrometry [16,17], which are not always convenient.
Moreover, gas chromatography methods require a derivatization step [22]. Enzymatic and colorimetric
methods are time-consuming and do not allow a simultaneous measurement of both sugars. 1H NMR
spectroscopy is a rapid and convenient method without any additional sample preparation for the
analysis of urinary sugars in a single analysis. In the present study, we first elucidated the potential
of using 1H NMR spectroscopy for quantification of L/M ratio in an IP test with the ingestion of
non-metabolizable lactulose (L) and mannitol (M) in preterm piglets with a gastrointestinal disorder.
Correlation analysis between urinary L/M ratios determined by a standard measurement by enzymatic
assays and L/M ratios determined by 1H NMR spectroscopy showed high correlations (r = 0.93). Thus, it
was evident that significantly-correlated values to standard measurement were obtained with the
applied NMR methodology, and the study demonstrated the usefulness of 1H NMR spectroscopy for
a simple and reliable quantification of L/M ratios in urine. 1H NMR spectroscopy has the advantages of
being rapid and non-invasive, and offers simple sample preparation. Former studies have investigated
the use of 1H NMR spectroscopy for a simple and reliable quantification of L/M ratio in urine from
healthy subjects [23] and subjects suffering from liver disease and malabsorption syndrome [20,24].
In this work, the use of a projected J-resolved NMR experiment was demonstrated to be useful for
quantification of the L/M ratio [23]. To the best of our knowledge, the present study is the first to
examine the use of NMR spectroscopy for quantification of L/M ratios in a model resembling infants.
To combine the L/M quantification with a simultaneous metabolomics analysis, a one-dimensional
nuclear Overhauser effect spectroscopy (1D NOESY) NMR experiment was applied.
3.2. Biomarker Exploration
Since 1H NMR spectroscopy is a non-selective technique that allows for the detection of numerous
low-molecular weight proton-containing metabolites, the NMR-based analysis of L/M ratio enabled
the simultaneous measurement of several other abundant metabolites present in urine which may
reflect alterations in the gastrointestinal system. Furthermore, the NMR-based metabolomics approach
was extended to also include measurements on blood to be able to explore potential blood metabolites
related to IP. By employing PLS regressions and correlation analyses, the present study revealed
significant correlations between IP and plasma and urine level plasma lactate, succinate, citrate, acetate,
and 2-hydroxybutyrate, as well as urine hippuric acid, fumarate, and glycine. Thus, the findings
suggest that perturbations in these metabolites may reflect conditions associated with intestinal barrier
dysfunctions. To our knowledge, this is the first study to investigate the systemic metabolite alterations
and perturbations associated with an increased IP by using a 1H NMR spectroscopic approach.
The present study showed that the IP has a significant positive correlation with plasma lactate.
An intestinal disorder or dysbiosis may lead to an increased number of bacteria in the lumen of the
infected intestine by efflux due to the impaired intestinal permeability and host defenses against
bacterial overgrowth [25,26]. This bacterial proliferation could lead to an enhanced generation of
bacterial metabolites and fermentation products. Lactate is the intermediate product of bacterial
fermentation produced by many bacteria found in the gastrointestinal tract including Klebsiella,
Lactobacillus species, Escherichia coli, and Bacteroides species [27], and are further metabolized to acetate.
Succinate, in addition to other metabolites, is also produced by some bacteria as the end product
of glucose fermentation. Products of bacteria metabolism can leak into the blood circulation due to
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an injured mucosa and increased IP in the disease process [25]. Thus, the accumulation of the bacteria
fermentation products in the systemic circulation can reflect impaired gut permeability induced by
some gastrointestinal disorders. Furthermore, metabolites such as lactate and succinate may also
derive from the host’s own endogenous metabolism and reflect disruption of the host’s homeostasis
under inflamed conditions.
In this study, an impaired IP was negatively correlated to urinary glycine. Results of some
studies suggest that higher levels of glycine are linked to an improved intestinal mucosal barrier
function, which is explained by a stimulation of protein synthesis and preservation of the intracellular
redox states in enterocytes in piglets [28–30]. Furthermore, glycine concentration in the plasma of
low-birth-weight neonates has been found to be lower in comparison to their normal-birth-weight
counterparts [31]. Therefore, our findings corroborate other studies and suggest a possible association
between a reduced glycine level in urine and intestinal dysfunction in preterm piglets.
The present study identified a negative correlation between IP and urinary levels of hippuric
acid. Hippuric acid is a urinary host-bacterial co-metabolite, and its biosynthesis involves two phases,
including gut microbial metabolism of aromatic dietary compounds to benzoate following conjugation
of benzoate with glycine. Even though dietary benzoate can lead to differences in the urine hippuric
acid levels [32], its lower level is reported in inflammatory bowel diseases and Crohn’s disease due to
an altered gut microbial metabolism [33,34]. Alterations in the urine level of hippuric acid may thus
reflect systemic effects of an altered gut microbial metabolism.
4. Materials and Methods
4.1. Animal Experimental Procedures
All animal experiments were approved by the Danish National Committee of Animal
Experimentation. To investigate the IP and metabolic influences of prenatal lipopolysaccharide
(LPS), five pregnant sows (Large White × Danish Landrace × Duroc) were operated by laparotomy at
d 103 of gestation (term at 117 ± 2 days of gestation), and every fetus received an IA dose of 1 mg LPS
(from E.coli 055:B5, Sigma Aldrich, Copenhagen, Denmark) in an area near to the mouth, as previously
described [24]. Afterward, cesarean section was performed to deliver the preterm pigs at d 106 (89–92%
gestation age). A detailed description of the animal procedure and nutritional composition can be found
elsewhere [35–37]. Clinical circumstances and fecal features were assessed twice daily as previously
described [24]. The animal procedures were all approved by the Danish National Committee on
Animal Experimentation (2014-15-0201-00418).
4.2. Intestinal Permeability Test
The IP was evaluated by providing an enteral bolus of 15 mL/kg of a 5% lactulose (Sigma-Aldrich,
Copenhagen, Denmark) and 5% mannitol solution (Sigma-Aldrich, Copenhagen, Denmark) exactly
3 h before euthanasia. Urine was collected at the time of euthanasia and stored at −20 ◦C until
assayed. Concentrations of lactulose and mannitol were measured in urine by an enzymatic
spectrophotometric method (Pentra 400, Irvine, CA, USA). In the presence of mannitol dehydrogenase,
mannitol was oxidized by NAD into the fructose and NADH. The amount of NADH was detected by
spectrophotometry at 340 nm. Lactulose was also hydrolyzed into galactose and fructose. Fructose
was then catalyzed into fructose-6-phosphate and to glucose-6-phosphate by phosphoglucoisomerase.
Glucose-6-phosphate was dehydrogenated by adding glucose-6-phosphate-dehydrogenase in the
presence of NADP to form NADPH. The concentration of NADPH is proportional to the concentration
of lactulose and can be measured spectrophotometrically at 340 nm. L/M ratios quantified by enzymatic
assay are provided in the Supplementary Materials.
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4.3. NMR Sample Preparation
Amicon Ultra 0.5-mL 3 kDa (Millipore, Billerica, MA, USA) was used to filter the thawed plasma
samples at 10,000× g at 4 ◦C for 3 h to remove lipid and proteins. For NMR measurement, 300 µL plasma
sample, 250 µL D2O and 50 µL D2O containing 0.05% sodium trimethylsilyl-[2,2,3,3-2H4]-1-propionate
(TSP; Sigma-Aldrich, St. Louis, MO, USA) as an internal chemical shift reference was added to a 5 mm
NMR tube (Wilmad, Vineland, NJ, USA). For the urine samples, 100 µL phosphate buffer in D2O [38]
(pH = 7.4) containing 0.05% TSP was transferred to 500 µL of thawed urine in a 5 mm NMR tube.
4.4. NMR Data Acquisition and Preprocessing
NMR spectra were recorded on a Bruker Avance III 600 MHz NMR spectrometer (Bruker BioSpin
Gmbh, Rheinstettten, Germany) equipped with a 5-mm 1H TXI probe and operating at a 1H frequency
of 600.13 MHz. A target temperature of 298 K and a relaxation delay of 5 s were applied. A total of 128
free induction decays (FIDs) were acquired, and the acquisition parameters included 32,768 data points,
a spectral width of 7288 Hz and an acquisition time of 2.25 s. A one-dimensional nuclear Overhauser
effect spectroscopy (1D NOESY) experiment with a single 90◦ pulse sequence and pre-saturation of the
water resonance was conducted.
The spectra were processed with zero-filling prior to Fourier transformation. All spectra were
referenced to the TSP signal at 0.0 ppm. An experimental window function with a line-broadening
factor of 0.3 Hz was applied to all FIDs before Fourier transformation. The resulting spectra were
manually phase- and baseline-corrected by polynomial using the TopspinTM 3.0 software (Bruker
BioSpin, Gmbh, Rheinstetten, Germany). The NMR resonances were assigned based on 2D NMR
spectroscopy, the Human Metabolome Database [39], existing literature [40–42] and Chenomx NMR
Suite 7.7 (Chenomx Inc, Edmonton, AB, Canada).
4.5. Data Analysis
Quantitative analysis of metabolites was performed on data by the integration of peak areas
using TopspinTM 3.0 software (Bruker BioSpin, Gmbh, Rheinstetten, Germany). The metabolites were
quantified relative to the area under the TSP peak. The analysis was performed on quantified NMR
metabolites obtained from plasma and urine samples of the same piglets. The final NMR data sets
of plasma and urine had the size of 20 × 23 and 20 × 18, respectively, with the rows representing the
quantified metabolites of each piglet and the columns representing each of the quantified metabolites.
Linear regression was performed between the standard measurement of urinary L/M and the
quantified urine L/M ratio by NMR spectroscopy. To determine whether the IP was correlated with
the quantified metabolites of plasma and urine profiles, partial least squares (PLS) regressions were
performed between the quantified metabolites (X) and quantified urine L/M ratio by enzymatic assay
(y). Orthogonal signal correction (OSC) [43] was performed on the X matrix and the data were
autoscaled prior to PLS regressions. The quality of the model was evaluated by the goodness-of-fit
parameter R2 and the predictive ability parameter Q2 using the leave-one-out validation. Variable
importance in projection (VIP) scores were calculated to evaluate the importance of each metabolite
in the projection used in a PLS model [44]. The metabolites with VIP scores greater than 1.0 were
regarded as important variables.
Moreover, Pearson’s correlations between quantified plasma and urine metabolites and the
urinary L/M ratio quantified by NMR spectroscopy were calculated and coefficients and p-values of
correlations were evaluated. The concentration of the quantified metabolites as well as the L/M ratios
quantified by NMR spectroscopy are provided in the Supplementary Materials. Matlab (version R2016b,
MathWorks Inc., Middlesex, MA, USA) was used for data analysis and visualization.
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5. Conclusions
NMR-based metabolomics analysis of LPS-induced preterm piglets revealed that 1H -NMR
spectroscopy is a reliable and rapid technique to estimate the L/M ratio in urine samples. To our
knowledge, this is the first study that has combined NMR-based L/M determination with NMR-based
metabolomics to assess IP biomarkers in preterm piglets with systemic inflammation. Our findings
suggest that increased plasma lactate, acetate, and succinate levels, as well as decreased levels of
urinary hippuric acid and glycine can be considered potential markers of an impaired IP induced by
gastrointestinal disorders.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/1/22/s1,
Figure S1: Leave-one-out cross validation for PLS model (a) and (b) plasma NMR data, (c) and (d) urine NMR
data. (a) Q2 value for PLS on plasma data, and (b) RMSECV for PLS model on plasma data. (a) Q2 value for PLS
on urine data, and (b) RMSECV for PLS model on urine data.
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